Recent developments include the spin-off and separation from the former parent company in May 2024, completion of a merger transferring certain assets to Sanofi, and positive clinical trial results for ozekibart in chondrosarcoma and other oncology indications. The company is exploring strategic alternatives for monetizing ozekibart.

• In May 2024, Inhibrx completed a spin-off from its former parent, acquiring assets related to INBRX-106, ozekibart, and its discovery pipeline, and became a stand-alone publicly traded company [S1].
• The former parent merged with a Sanofi subsidiary, transferring the INBRX-101 program to Sanofi, while Inhibrx retained other clinical programs and infrastructure [S1].
• In October 2025, ozekibart met its primary endpoint in a registrational trial for advanced or metastatic chondrosarcoma, showing a 52% reduction in risk of progression or death compared to placebo [S1].
• Interim data from ozekibart trials in colorectal adenocarcinoma and Ewing sarcoma showed disease control rates of 92% and 87.1%, respectively, with ongoing enrollment and data maturation [S1].
• Inhibrx is exploring potential alternatives for monetizing ozekibart, focusing on tax efficiency and stockholder value, with associated risks including management distraction and uncertain outcomes [S2].

Inhibrx has demonstrated clinical progress with ozekibart showing statistically significant improvement in progression-free survival in a registrational trial for chondrosarcoma, a disease with no approved systemic therapies. Positive interim data in colorectal adenocarcinoma and Ewing sarcoma cohorts indicate potential broader applicability. The proprietary protein engineering platforms enable the development of next-generation therapeutics with optimized mechanisms, potentially overcoming limitations of prior approaches. The company’s strategic focus on high unmet medical need areas and its experienced leadership team support continued clinical advancement. The exploration of strategic alternatives for ozekibart may provide opportunities to enhance value and accelerate development timelines.

Inhibrx faces significant clinical and regulatory risks inherent in developing novel biologic therapeutics, including the uncertainty of clinical trial outcomes and potential safety issues such as hepatotoxicity observed with DR5 agonists. The company reported a substantial net loss and relies on external financing, including a significant loan secured by its assets, which may constrain operational flexibility. The competitive biopharmaceutical environment includes numerous companies developing similar or alternative therapies, which may limit market opportunities. Efforts to monetize ozekibart may not result in a transaction or achieve desired objectives, potentially causing operational distractions and adverse market perceptions. The company’s status as an emerging growth and smaller reporting company may affect investor interest and stock liquidity.

Inhibrx's moat is based on its proprietary modular protein engineering platforms that enable the design of differentiated biologic therapeutics with optimized valency and target-specific mechanisms. The company's focus on challenging, validated targets such as DR5 and OX40, combined with its ability to engineer multivalent agonists tailored to target biology, provides a scientific and technological advantage. Its in-house capabilities spanning discovery, manufacturing, clinical development, and commercialization, along with a leadership team experienced in protein therapeutics, support efficient development and potential market entry. The clinical-stage pipeline with positive trial data, particularly for ozekibart, and regulatory designations such as Fast Track and orphan drug status, further strengthen its competitive position. However, the company operates in a highly competitive biopharmaceutical landscape with numerous established and emerging players.

• Clinical Development Risks: The success of Inhibrx’s therapeutic candidates depends on clinical trial outcomes, which are inherently uncertain. Safety concerns such as hepatotoxicity with DR5 agonists may limit clinical utility or require mitigation strategies.
• Financial Risks: The company reported significant net losses and relies on debt financing secured by its assets. Failure to comply with loan covenants or inability to raise additional capital could adversely affect operations.
• Competitive Risks: Inhibrx operates in a highly competitive biopharmaceutical industry with many companies developing similar biologics and alternative therapies, which may impact market share and commercial success.
• Strategic Transaction Risks: Efforts to monetize ozekibart may not result in a transaction or deliver anticipated benefits, potentially causing management distraction and negative investor perceptions.
• Regulatory and Market Risks: As an emerging growth and smaller reporting company, Inhibrx may face challenges in investor perception, stock liquidity, and compliance with evolving regulatory requirements.

• Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms [S1].
• The company was spun off from Inhibrx, Inc. in May 2024, acquiring assets related to its ongoing clinical programs INBRX-106 and ozekibart (INBRX-109) and its discovery pipeline [S1].
• Inhibrx operates as a stand-alone publicly traded company focused on two clinical-stage programs: ozekibart (INBRX-109), a tetravalent DR5 agonist, and INBRX-106, a hexavalent OX40 agonist [S1].
• Ozekibart targets death-receptor 5 (DR5) to induce cancer-specific programmed cell death and is being investigated in chondrosarcoma, Ewing sarcoma, colorectal cancer, and other solid tumors [S1].
• INBRX-106 targets OX40, a co-stimulatory receptor on activated T-cells, aiming to enhance anti-tumor immunity; it is being investigated in non-small cell lung cancer and head and neck squamous cell carcinoma [S1].
• The company completed a registrational trial for INBRX-101 (alpha-1 antitrypsin augmentation therapy) which was spun off and transferred to Sanofi in 2024 [S1].
• Ozekibart has demonstrated positive clinical data including a statistically significant improvement in progression-free survival in a registrational trial for advanced or metastatic chondrosarcoma, with a 52% reduction in risk of progression or death compared to placebo [S1].
• Clinical trials for ozekibart in colorectal adenocarcinoma and Ewing sarcoma have shown disease control rates of 92% and 87.1%, respectively, with ongoing enrollment and data collection [S1].
• INBRX-106 is in Phase 1/2 clinical trials with objectives including safety, tolerability, and anti-tumor efficacy, with preclinical data showing superior OX40 agonism compared to bivalent antibodies [S1].
• The company has a leadership team with experience from major pharmaceutical companies and in-house capabilities spanning discovery, protein engineering, clinical development, and commercialization [S1].
• Inhibrx reported financial figures for the fiscal year ended December 31, 2025, including revenue of $1.3 million, net loss of $140.1 million, and negative EPS of $9.04 per share [S1].
• As of December 31, 2025, the company held $124.2 million in cash and cash equivalents, with current assets of $132.8 million and current liabilities of $33.8 million, resulting in a current ratio of 3.93 and a cash ratio of 3.68 [S1].
• The company has a loan agreement with Oxford Finance LLC with total borrowings of $175 million as of early 2026, secured by substantially all assets and subject to restrictive covenants [S1].
• Inhibrx is exploring potential alternatives for monetizing ozekibart, focusing on tax efficiency and stockholder value, but such efforts may be costly, time-consuming, and may not result in a transaction [S2].
• The company leases approximately 43,000 square feet of laboratory and office space in La Jolla, California, with a lease expiring in 2028 and an option to extend [S1].
• Inhibrx is classified as an emerging growth company and a smaller reporting company, which affects its reporting requirements and may influence investor perceptions [S1].
• The company faces competition from other biopharmaceutical firms developing novel therapeutics, including those based on single domain antibodies and alternative scaffolds, as well as companies developing therapies for autoimmune diseases and oncology [S1].
• No material legal proceedings are currently pending against the company [S1].